Axsome Therapeutics (NASDAQ:AXSM) PT Raised to $95.00 at Mizuho

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) had its target price boosted by investment analysts at Mizuho from $84.00 to $95.00 in a note issued to investors on Thursday, The Fly reports. Mizuho’s target price would suggest a potential upside of 20.24% from the company’s current price.

A number of other research firms have also recently commented on AXSM. Bank of America reaffirmed an “underperform” rating and issued a $52.00 target price on shares of Axsome Therapeutics in a research report on Tuesday, February 14th. StockNews.com started coverage on shares of Axsome Therapeutics in a research note on Thursday, March 16th. They issued a “sell” rating on the stock. Morgan Stanley increased their price objective on Axsome Therapeutics from $83.00 to $87.00 in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Axsome Therapeutics in a report on Monday, April 17th. Finally, Guggenheim increased their price target on Axsome Therapeutics from $90.00 to $100.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $105.57.

Axsome Therapeutics Price Performance

Axsome Therapeutics stock opened at $79.01 on Thursday. The stock has a market cap of $3.44 billion, a price-to-earnings ratio of -20.79 and a beta of 1.90. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.54 and a quick ratio of 2.50. Axsome Therapeutics has a 1 year low of $20.63 and a 1 year high of $82.85. The firm has a 50-day moving average of $66.74 and a two-hundred day moving average of $66.30.

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last issued its quarterly earnings results on Monday, February 27th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.10). The business had revenue of $24.37 million for the quarter, compared to analyst estimates of $21.51 million. On average, research analysts forecast that Axsome Therapeutics will post -4.37 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors raised its stake in Axsome Therapeutics by 582.0% in the first quarter. Captrust Financial Advisors now owns 757 shares of the company’s stock valued at $31,000 after buying an additional 646 shares during the period. Armstrong Advisory Group Inc. acquired a new stake in shares of Axsome Therapeutics in the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Axsome Therapeutics by 33.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 589 shares of the company’s stock valued at $36,000 after purchasing an additional 148 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Axsome Therapeutics by 141.1% in the 1st quarter. Tower Research Capital LLC TRC now owns 815 shares of the company’s stock valued at $50,000 after acquiring an additional 477 shares during the last quarter. Finally, Dark Forest Capital Management LP bought a new position in shares of Axsome Therapeutics in the 1st quarter valued at $51,000. 59.71% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

(Get Rating)

Axsome Therapeutics, Inc is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14.